Effects of a human-derived sodium transport inhibitor on in vitro vascular reactivity.
Concentrations of sodium-transport inhibitors (STI) which block the sodium-potassium-ATPase pump are increased in the plasma and urine of volume-expanded and low-renin hypertensive humans and animals. To evaluate the physiologic relevance of STI to blood-pressure-raising mechanisms, we have examined the in vitro properties of STI extracted from the urine of human subjects. STI produced a significant (by ANOVA: P less than .01) dose-contraction response in the isolated rabbit femoral artery. Moreover, small noncontractile doses of STI in this in vitro preparation produced a fivefold leftward shift in the contraction dose-response curve of norepinephrine (P less than .01) and a threefold shift for angiotensin II (P less than .01); at lower, physiologic, concentrations of these vasoconstrictor hormones the amplifications in contraction caused by STI ranged from 100% to 500%. In studies in calcium-free tissue bath solutions, the direct contractile action of STI was abolished; however, its amplification of responses to norepinephrine remained, suggesting that this latter effect of STI is not entirely dependent upon calcium influx into vascular smooth muscle cells. The glycoside ouabain produced effects identical to those of STI in arteries, but its actions on a rabbit atrium preparation were different: ouabain stimulated powerful inotropic effects, whereas human STI failed to cause myocardial contractions even though the amounts of STI administered had the same sodium-transport inhibitory capacity as the ouabain. Thus, the actions of human STI are primarily in the peripheral circulation, where they directly produce arterial contractions and also enhance contractile responses to other pressor hormones, suggesting that they may have a role in regulating systemic blood pressure.
Weber
M A
MA
Hypertension Center, Veterans Administration Medical Center, Long Beach, California 90822.
Weiler
E
E
Gonick
H C
HC
Prins
B A
BA
Purdy
R E
RE
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001693:Biological Transport, Active; D001808:Blood Vessels / Q000187:drug effects* / Q000502:physiology; D002118:Calcium / Q000494:pharmacology; D003000:Clonidine / Q000494:pharmacology; D003470:Culture Media; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D007265:Inhibins / Q000494:pharmacology*; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D009994:Osmolar Concentration; D010042:Ouabain / Q000494:pharmacology; D011817:Rabbits; D014661:Vasoconstriction
D003470:Culture Media; D000804:Angiotensin II; D007265:Inhibins; D010042:Ouabain; D003000:Clonidine; D002118:Calcium; D009638:Norepinephrine